Engelstad Foundation Donates $1.5 Million Toward Wave Neuroscience’s Phase Two Trial for PTSD and TBI Treatment

Wave Neuroscience announced today the receipt of a generous $1.5 million grant from the Engelstad Foundation that will support Wave Neuroscience’s Phase Two clinical trial currently underway with Texas A&M University Health Science Center (Texas A&M Health) Institute of Biosciences and Technology. This significant contribution will accelerate the trial, which aims to develop and validate innovative treatments for Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).

Wave Neuroscience is at the forefront of developing personalized non-invasive therapies for mental health conditions. Their ongoing FDA trial will evaluate the effectiveness of their pioneering technology, Magnetic EEG-guided Resonance Therapy™ (MeRT^TM) in treating PTSD and TBI. With this generous funding from the Engelstad Foundation, Wave Neuroscience will be able to accelerate the trial and potentially pave the way for groundbreaking treatment options.

"We are deeply grateful for the Engelstad Foundation's incredible generosity and support," said Fred Walke, Wave’s CEO. "Their donation will significantly accelerate our efforts to bring new, effective treatments to individuals suffering from PTSD and TBI. We look forward to the potential impact this will have on mental health care."

The Engelstad Foundation is committed to making a difference in the community and improving the lives of individuals through its philanthropic endeavors. This donation is a testament to the Foundation's commitment to fostering innovation and supporting valuable health initiatives.

“Wave Neuroscience is on the frontlines with such a compassionate mission - to help improve the lives of those with PTSD and TBI,” says Kris Engelstad, trustee of the Engelstad Foundation. “We see this grant as not only an investment in Wave Neuroscience’s incredible treatment efforts and research, but the ultimate wellbeing of so many out there.”

PTSD can result from experiencing or witnessing a traumatic event, and the symptoms put a person at greater risk for depression, substance abuse, and a host of psychological disorders. In 2020, approximately 13 million people were suffering from PTSD in the United States (National Center for PTSD). PTSD is often coupled with TBI, and there were approximately 214,110 TBI-related hospitalizations in 2020 (U.S. Centers for Disease Control).

If you are interested in financially supporting this groundbreaking work, please email Mary Callan, Ph.D., at mary@waveneuro.com, or call 949.229.0586.

If you are interested in enrolling in this trial or would like to learn more about it, please visit https://www.mertptsdtrial.com.

About Wave Neuroscience:

Wave Neuroscience is a leading organization in mental health care, developing non-invasive therapies for mental health conditions. They are committed to pioneering research and delivering effective treatment options for individuals affected by PTSD, TBI, and other conditions. Learn more about Wave Neuroscience at www.waveneuro.com.

About Texas A&M Health:

Texas A&M University Health Science Center (Texas A&M Health) comprises five schools (dentistry, medicine, nursing, pharmacy and public health), an integrated University Health Services model, several research centers and institutes, and numerous outpatient clinics with a shared mission of advancing health care for all. We serve the state and beyond with campuses and locations in Bryan-College Station, Dallas, Temple, Houston, Round Rock, Kingsville, Corpus Christi, McAllen and Navasota. Learn more at health.tamu.edu or follow @TAMUHealth on Twitter.

About Engelstad Foundation:

The Engelstad Foundation was created in 2002 by Ralph & Betty Engelstad for the purpose of partnering to create solutions in medical research, improving day to day living for people with disabilities and raising the possibilities for high-risk individuals. Since its inception, the Foundation has provided more than $500 million in grants to organizations focused on animal compassion, at-risk individuals, education, historical preservation, medical research and support, people with disabilities and veterans. For additional information, visit www.engelstadfoundation.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108783792/en/